A clinical-stage biotechnology company in Lexington, Massachusetts, developing emavusertib, an oral pill for blood cancers like primary central nervous system lymphoma and chronic lymphocytic leukemia. Formed in 2000 from the merger of three Boston-area biotech firms, its logo carries a musical fermata—a symbol that holds a note—reflecting its goal of prolonging life and curing cancer. Curis also helped develop Erivedge, an approved treatment for advanced basal cell carcinoma.
Curis reports zero revenue and $5.1M in cash, funding operations only into Q4 2026.
Curis burned through nearly all its cash and now has no . The net loss widened to $8.6 million from $8.6 million a year earlier, as a $10.5 million non-cash charge from a change in offset lower operating expenses, while cash and equivalents fell to $5.1 million. The company can fund operations only into the fourth quarter of 2026 and has substantial doubt about its ability to continue.
Key takeaways
fell 100% to $0, as the November 2025 sale of the Erivedge royalty subsidiary eliminated the royalty stream that had been the company's sole source of income.
The net loss was $8.6 million, flat against the prior-year period, as an $11.3 million non-cash other expense—driven by a change in the fair value of from the January 2026 —offset an 18% decline in research and development expenses to $13.2 million for the six months.
Section summaries
Management's Discussion and Analysis
Curis has no revenue, a $32.8M net loss, and cash to fund operations only into Q4 2026, raising substantial doubt about its ability to continue as a going concern.
⌄
Revenues fell to zero from $5.1M in the prior-year period following the November 2025 sale of Erivedge, eliminating royalty income.
Research and development expenses decreased 18% to $13.2M for the six months, driven by lower employee-related, clinical, and manufacturing costs.
Cash and cash equivalents fell to $5.1 million as of June 30, 2026, down 50% from $10.1 million a year earlier and down 66% from $15.0 million at the end of the prior quarter, after the company raised $4.8 million in an August 2026 offering.
Management stated that existing cash and the August 2026 proceeds are expected to fund operations only into the fourth quarter of 2026, and there is substantial doubt about the company's ability to continue as a .
The company effected a 1-for-20 in July 2026 to regain compliance with Nasdaq's minimum bid price rule, but remains under a one-year discretionary panel monitor where any new deficiency would trigger immediate delisting proceedings.
What changed
The Q1 FY2026 filing flagged whether the Nasdaq hearing panel would grant Curis additional time to regain compliance with the $1.00 minimum bid price requirement. The company regained compliance after a 1-for-20 in July 2026, but now faces a one-year discretionary panel monitor.
The Q1 FY2026 filing flagged whether additional financing would extend the cash runway. An August 2026 offering raised $4.8 million, but management still expects funds to run out in Q4 2026, leaving the going-concern warning in place.
The Q1 FY2026 filing flagged the quarterly cash burn rate relative to the $15.0 million balance. Cash fell to $5.1 million at quarter-end, a $9.9 million decline in a single quarter, accelerating the path toward a liquidity crisis.
What to watch
Whether Curis secures additional financing before cash runs out in Q4 2026, given management's statement that current funds are insufficient to sustain operations beyond 12 months.
Any initial data from the TakeAim CLL trial for emavusertib, which management previously guided for the fourth quarter of 2026, as the company's sole remaining asset.
Whether the post-reverse-split share price holds above $1.00, given the one-year Nasdaq panel monitor that would trigger immediate delisting on any new deficiency.
Quarterly cash burn rate relative to the $5.1 million balance and $4.8 million August raise, to track whether the Q4 2026 runway projection holds.
General and administrative expenses rose 10% to $8.3M for the six months, primarily due to costs from the January 2026 and higher legal fees.
Other expense increased by $10.5M to $11.3M for the six months, mainly from a change in the fair value of warrant liabilities tied to the January 2026 .
Cash and equivalents stood at $5.1M as of June 30, 2026, with an additional $4.8M raised in August 2026, expected to fund operations only into the fourth quarter of 2026.
Management states that current cash is not sufficient to fund operations beyond 12 months, and the company's ability to continue as a is in substantial doubt without immediate additional funding.
Quantitative and Qualitative Disclosures About Market Risk
We are a smaller reporting company, as defined by Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and in Item 10(f)(1) of Regulation S-K, and are not required to provide the information under this item. 32 Table of Contents
⌄
We are a smaller reporting company, as defined by Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and in Item 10(f)(1) of Regulation S-K, and are not required to provide the information under this item.
32
Table of Contents
Substantial doubt exists about the company's ability to continue as a going concern, with cash runway only into Q4 2026.
⌄
Management has concluded there is substantial doubt about the company's ability to continue as a , with existing cash and recent offering proceeds expected to fund operations only into Q4 2026.
The company requires substantial additional funding to develop its sole product candidate, emavusertib, through approval and commercialization, and failure to secure capital will force delays, scope reductions, or elimination of the program.
If unable to raise sufficient funds, the company may pursue strategic alternatives including partnerships, asset sales, or a sale of the company, and could ultimately dissolve, liquidate, or seek bankruptcy protection.
Despite recently regaining compliance with Nasdaq's minimum bid price rule, the company remains under a one-year discretionary panel monitor, and any new deficiency would immediately trigger delisting proceedings with no opportunity for a compliance plan.
The July 2026 1-for-20 may reduce trading liquidity, increase odd-lot holders, and fail to attract institutional investors if the post-split share price does not meet their guidelines.